Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025
Cash flows from operating activities
Net income (loss)	$ (72,478)	$ (181,074)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	18,295	18,137
Noncash lease expense	1,884	3,407
Stock-based compensation expense	47,581	7,845
Net accretion and amortization of investments in marketable securities	(2,689)	(3,101)
Loss on fair-value remeasurement of convertible note	11,731	0
Loss from disposal of property and equipment	0	31
Non-cash interest expense and amortization of debt issuance costs	7,701	0
Changes in operating assets and liabilities:
Accounts receivable	(7,514)	82
Inventory	(1,885)	0
Prepaid expenses and other current assets	(11,787)	(811)
Other long-term assets	0	269
Accounts payable	3,979	1,297
Accrued compensation and other related benefits	(958)	(2,084)
Accrued expenses and other current liabilities	30	1,026
Deferred revenue	(31,667)	8,400
Operating lease liabilities	(7,470)	4,894
Other long term liabilities	(13,449)	0
Net cash used in operating activities	(58,696)	(141,682)
Cash flows from investing activities
Purchases of marketable securities	(271,573)	(119,210)
Proceeds from maturities of marketable securities	162,300	246,600
Purchases of property and equipment	(15,248)	(20,349)
Net cash (used in) provided by investing activities	(124,521)	107,041
Cash flows from financing activities
Proceeds from issuance of common stock upon Business Combination and PIPE Financing	295,490	0
Payments made on finance leases	0	(159)
Proceeds from convertible note	0	41,600
Convertible note issuance costs	0	(294)
Payments for taxes related to net settlement of equity awards	(1,096)	0
Payments of transaction costs related to the Business Combination	(8,895)	0
Proceeds from issuance of common stock upon exercise of stock options	0	390
Net cash provided by financing activities	285,499	41,537
Effect of exchange rate changes on cash and cash equivalents and restricted cash	(19)	35
Net increase in cash, cash equivalents and restricted cash	102,263	6,931
Cash, cash equivalents and restricted cash at beginning of period	87,676	76,170
Cash, cash equivalents and restricted cash at end of period	189,939	83,101
Reconciliation to amounts on the Condensed Consolidated Balance Sheets:
Cash and cash equivalents	180,379	73,983
Restricted cash	9,560	9,118
Total cash, cash equivalents and restricted cash	189,939	83,101
Supplemental disclosures of cash flow information:
Lease liabilities arising from obtaining right-of-use assets	0	3
Supplemental disclosures of noncash investing and financing activities:
Purchases of property and equipment in accounts payable and accrued expenses	994	77
Offering expenses included in accounts payable	778	0
Deferred offering costs related to reverse recapitalization	841	0
Issuance of common stock upon conversion of convertible notes	122,396	0
Conversion of redeemable convertible preferred stock into common stock in connection with reverse recapitalization	$ 1,363,580	$ 0